137 related articles for article (PubMed ID: 10505768)
1. Treatment of follicular and other indolent lymphomas.
McLaughlin P
Curr Opin Oncol; 1999 Sep; 11(5):333-8. PubMed ID: 10505768
[TBL] [Abstract][Full Text] [Related]
2. Considerations with newer regimens for indolent non-Hodgkin lymphoma.
Rummel M
Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S128-36. PubMed ID: 18952543
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic advances for indolent lymphomas].
Ogura M
Nihon Rinsho; 2000 Mar; 58(3):682-94. PubMed ID: 10741147
[TBL] [Abstract][Full Text] [Related]
4. Bispecific antibodies in indolent B-cell lymphomas.
Radhakrishnan VS; Davies AJ
Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
[TBL] [Abstract][Full Text] [Related]
5. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W
Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420
[TBL] [Abstract][Full Text] [Related]
6. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
7. Treatment approaches to asymptomatic follicular lymphoma.
Sarkozy C; Salles G
Expert Rev Hematol; 2013 Dec; 6(6):747-58. PubMed ID: 24219551
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
Fanale MA; Younes A
Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
[TBL] [Abstract][Full Text] [Related]
9. Current treatment of follicular non-Hodgkin's lymphoma.
Reiser M; Diehl V
Eur J Cancer; 2002 Jun; 38(9):1167-72. PubMed ID: 12044501
[TBL] [Abstract][Full Text] [Related]
10. Rituximab maintenance therapy in indolent NHL: a clinical review.
Buske C; Hiddemann W
Leuk Res; 2006 Mar; 30 Suppl 1():S11-5. PubMed ID: 16750673
[TBL] [Abstract][Full Text] [Related]
11. What is the role of maintenance rituximab in follicular NHL?
Maloney DG
Oncology (Williston Park); 2008 Jan; 22(1):20-6; discussion 26, 29, 33-4. PubMed ID: 18251281
[TBL] [Abstract][Full Text] [Related]
12. Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects.
Maloney DG
Hematology Am Soc Hematol Educ Program; 2007; ():226-32. PubMed ID: 18024634
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of follicular lymphoma].
Buske C; Unterhalt M; Hiddeman W
Internist (Berl); 2007 Apr; 48(4):372-81. PubMed ID: 17287964
[TBL] [Abstract][Full Text] [Related]
14. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?
Raynaud P; Caulet-Maugendre S; Foussard C; Salles G; Moreau A; Rossi JF; Patey M; Rousselet MC; Bene MC; Damotte D; Cornillet Lefebvre P; Martin A; Costes V;
Hum Pathol; 2008 Feb; 39(2):194-200. PubMed ID: 17949786
[TBL] [Abstract][Full Text] [Related]
15. Novel treatment strategies in follicular lymphoma.
Buske C; Dreyling H; Unterhalt M; Hiddemann W
Ann Hematol; 2004; 83 Suppl 1():S72. PubMed ID: 15124680
[TBL] [Abstract][Full Text] [Related]
16. Current status and perspective of antibody therapy in follicular lymphoma.
Buske C; Weigert O; Dreyling M; Unterhalt M; Hiddemann W
Haematologica; 2006 Jan; 91(1):104-12. PubMed ID: 16434378
[TBL] [Abstract][Full Text] [Related]
17. Indolent lymphomas: current and emerging treatment approaches.
Maloney D; Kahl BS; Dreyling M
Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
[TBL] [Abstract][Full Text] [Related]
18. [Rituximab (antiCD20 monoclonal antibody) and molecular-biological negativity in the treatment of patients with follicular lymphoma--a way to a cure?--Editorial].
Trnený M
Vnitr Lek; 2007 Oct; 53(10):1029-30. PubMed ID: 18072423
[No Abstract] [Full Text] [Related]
19. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
20. AntiCD20 mAbs: modifying therapeutic strategies and outcomes in the treatment of lymphoma patients.
Grillo-López AJ
Expert Rev Anticancer Ther; 2002 Jun; 2(3):323-9. PubMed ID: 12113055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]